Pre-treatment neutrophil to lymphocyte ratio may be a useful tool in predicting survival in early triple negative breast cancer patients

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Pistelli, Mirco ^a   De Lisa, Mariagrazia ^a   Ballatore, Zelmira ^a   Caramanti, Miriam ^a   Pagliacci, Alessandra ^a   Battelli, Nicola ^a   Ridolfi, Francesca ^a   Santoni, Matteo ^a   Maccaroni, Elena ^a   Bracci, Raffaella ^a   Santinelli, Alfredo ^a   Biscotti, Tommasina ^a   Berardi, Rossana ^a   Cascinu, Stefano ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

Breast cancer; Lymphocyte; Neutrophil; Prognosis; Ratio; Survival; Triple negative

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EARLY CANCER; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; NEUTROPHIL COUNT; NEUTROPHIL LYMPHOCYTE RATIO; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; SURVIVAL PREDICTION; SURVIVAL RATE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; AGED; CARCINOMA, DUCTAL, BREAST; FEMALE; IMMUNOLOGY; KAPLAN MEIER METHOD; LYMPH NODE METASTASIS; LYMPHOCYTE; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPHIL; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; SECONDARY; TRIPLE NEGATIVE BREAST NEOPLASMS;

ADULT; AGED; CARCINOMA, DUCTAL, BREAST; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; LYMPHOCYTE COUNT; LYMPHOCYTES; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEUTROPHILS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; ROC CURVE; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84929158217     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1204-2     Document Type: Article

References (51)

1. Dent R, Trudeau M, Pritcherd KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple negative breast cancer: Clinical features and patterns of recurrence. Clin Cancer Res. 2013;1(13):4429-34.
2. Zhang J, Wang Y, Yin Q, Zhang W, Zhang T, Niu Y. An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. Int J Clin Exp Pathol. 2013;6(7):1380-91.
3. Brian D, Lehmann Joshua A, Bauer Xi C, Melinda E, Sanders A, Bapsi C, et al. Pietenpol: Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121(7):2750-67.
4. Pistelli M, Pagliacci A, Battelli N, Santinelli A, Biscotti T, Ballatore Z, et al. Prognostic factors in early-stage triple-negative breast cancer: lesson and limits from clinical practice. Anticancer Res. 2013;33(6):2737-42.
5. Zhou L, Li K, Luo Y, Tian L, Wang M, Li C, et al. Novel prognostic markers for patients with triple-negative breast cancer. Hum Pathol. 2013;44(10):2180-7.
6. Veer LJ V 't, Dai H, Van De Vijver MJ, He YD, Hart AA, Mao M, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530-6.
7. Balkwill FR, Mantovani A. Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol. 2012;22(1):33-40.
8. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer related inflammation. Nature. 2008;454(7203):436-44.
9. Gomez D, Farid S, Malik HZ, Young AL, Toogood G, Lodge JP, et al. Preoperative neutrophil-to-lymphocyte ratio as prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32(8):1757-62.
10. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010;13(3):170-6.
11. Guthrie GJ1, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke SJ. The systemic inflammation-based neutrophil-lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218-30.
12. Tomita M, Shimizu T, Ayabe T, Yonei A, Onitsuka T. Preoperative neutrophil to lymphocyte ratio as a prognostic predictor after curative resection for non-small cell lung cancer. Anticancer Res. 2011;31(9):2995-8.
13. Lee YY, Choi CH, Kim HJ, Kim TJ, Lee JW, Lee JH, et al. Pretreatment neutrophil: lymphocyte ratio as a prognostic factor in cervical carcinoma. Anticancer Res. 2012;32(4):1555-61.
14. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E. Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg. 2009;137(2):425-8.
15. Ohno Y, Nakashima J, Ohori M, Gondo T, Hatano T, Tachibana M. Follow up of neutrophil-to-lymphocyte ratio and recurrence of clear cell renal cell carcinoma. J Urol. 2012;187(2):411-7.
16. Kishi Y, Kopetz S, Chun YS, Palavecino M, Abdalla EK, Vauthey JN. Blood neutrophil-to-lymphocyte ratio predicts survival in patients with colorectal liver metastases treated with systemic chemotherapy. Ann Surg Oncol. 2009;16:614-22.
17. Noh H, Eomm M, Han A. Usefulness of pretreatment neutrophil to lymphocyte ratio in predicting disease-specific survival in breast cancer patients. J Breast Cancer. 2013;16(1):55-9.
18. Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short- and long-term mortality in breast cancer patients. Ann Surg Oncol. 2012;19(1):217-24.
19. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013;30(1):432-4.
20. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539-45.
21. Mantovani A, Marchesi F, Porta C, Sica A, Allavena P. Inflammation and cancer: breast cancer as a prototype. Breast. 2007;16 Suppl 2:S27-33.
22. Jansen MP, Foekens JA, van Staveren IL, Dirkzwager MM, Ritstier K, Look MP, et al. Molecular classification of tamoxifen resistan carcinomas by gene expression profiling. J Clin Oncol. 2005;23(4):732-40.
23. Chanrion M, Negre V, Fontaine H, Salvetat N, Bibeau F, Mac Grogan G, et al. A gene expression signature that can predict the recurrence of tamoxifene-treated primary breast cancer. Clin Cancer Res. 2008;14(6):1744-52.
24. Jiang X, Shapiro DJ. The immune system and inflammation in breast cancer. Mol Cell Endocrinol. 2014;382(1):673-82.
25. Fainaru O, Almog N, Yung CW, Nakai K, Montoya-Zavala M, Abdollahi A, et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells. FASEB J. 2010;24(5):1411-8.
26. Yu JL, Rak JW. Host microenvironment in breast cancer development: inflammatory and immune cells in tumour angiogenesis and arteriogenesis. Breast Cancer Res. 2003;5(2):83-8.
27. Kimbro KS, Simons JW. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer. 2006;13(3):739-49.
28. Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8 + lymphocytes predict clinical outcome in breast cancer. J Clin Oncol. 2011;29(15):1949-55.
29. West NR, Milne K, Truong PT, Macpherson N, Nelson BH, Watson PH. Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor negative breast cancer. Breast Cancer Res. 2011;13(6):R126.
30. De Palma M, Lewis CE. Cancer: Macrophages limit chemotherapy. Nature. 2011;472(7343):303-4.
31. Kristensen VN, Vaske CJ, Ursini-Siegel J, Van Loo P, Nordgard SH, Sachidanandam R, et al. Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling. Proc Natl Acad Sci U S A. 2012;109(8):2802-7.
32. Pierce BL, Ballard-Barbash R, Bernstein L, Baumgartner RN, Neuhouser ML, Wener MH, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-44.
33. Al Murri AM, Bartlett JM, Canney PA, Doughty JC, Wilson C, McMillan DC. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer. 2006;94(2):227-30.
34. Wang D-S, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Tumour Biol. 2012;33(3):749-56.
35. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007;73(3-4):215-20.
36. An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, et al. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15(6):516-22.
37. Santoni M, De Giorgi U, Iacovelli R, Conti A, Burattini L, Rossi L, et al. re-treatment neutrophil-to-lymphocyte ratio may be associated with the outcome in patients treated with everolimus for metastatic renal cell carcinoma. Br J Cancer. 2013;1(7):1755-9. 109.
38. McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12:223-6.
39. Webb NJ, Myers CR, Watson CJ, Bottomley MJ, Brenchley PE. Activated human neutrophils express vascular endothelial growth factor (VEGF). Cytokine. 1998;10:254-7.
40. Lee S, Oh SY, Kim SH, Lee JH, Kim MC, Kim KH, et al. Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer. 2013;13:350.
41. Jablonska E, Puzewska W, Grabowska Z, Jablonski J, Talarek L. VEGF, IL-18 and NO production by neutrophils and their serum levels in patients with oral cavity cancer. Cytokine. 2005;30(3):93-9.
42. Schmidt H, Bastholt L, Geertsen P, Christensen IJ, Larsen S, Gehl J, et al. Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma: a prognostic model. Br J Cancer. 2005;93(3):273-8.
43. Atzpodien J, Royston P, Wandert T, Reitz M. DGCIN - german cooperative renal carcinoma chemo-immunotherapy trials group: metastatic renal carcinoma comprehensive prognostic system. Br J Cancer. 2003;88(3):348-53.
44. Stanculescu A, Bembinster LA, Borgen K, Bergamaschi A, Wiley E, Frasor J. Estrogen promotes breast cancer cell survival in an inhibitor of apoptosis (IAP)-dependent manner. Horm Cancer. 2010;1(3):127-35.
45. Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233-47.
46. Terry MB, Gammon MD, Zhang FF, Tawfik H, Teitelbaum SL, Britton JA, et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk. JAMA. 2004;291(20):2433-40.
47. Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013;11(1):55-9.
48. Roxburgh CS, McMillan DC. Inflammatory scores are not interchangeable during the perioperative period of breast cancer surgery. Int J Surg. 2014;12(12):1360-2.
49. Loi S. Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy. Oncoimmunol. 2013;2(7):e24720.
50. Loi S, Michiels S, Salgado R, Sirtaine N, Jose V, Fumagalli D, et al. Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol. 2014;25(8):1544-50.
51. Dieci MV, Criscitiello C, Goubar A, Viale G, Conte P, Guarneri V, et al. Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study. Ann Oncol. 2014;25(3):611-8.